Nomura Holdings’s Nurix Therapeutics NRIX Stock Holding History

Nomura Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,514	Closed	-$198K	–	2203
2024 Q4	$198K	Buy	+10,514	New	+$241K	﹤0.01%	2050
2023 Q3	–	Sell	-130,040	Closed	-$1.3M	–	1560
2023 Q2	$1.3M	Sell	130,040 -158,800	-55%	-$1.62M	﹤0.01%	830
2023 Q1	$2.56M	Buy	288,840 +4,139	+1%	+$43.1K	0.01%	752
2022 Q4	$3.12M	Buy	284,701 +46,497	+20%	+$561K	0.01%	616
2022 Q3	$3.1M	Sell	238,204 -67,797	-22%	-$1.07M	0.01%	701
2022 Q2	$4.06M	Buy	306,001 +661	+0.2%	+$7.49K	0.01%	611
2022 Q1	$4.26M	Buy	305,340 +128,674	+73%	+$2.28M	0.01%	670
2021 Q4	$5.15M	Buy	176,666 +80,316	+83%	+$2.43M	0.01%	689
2021 Q3	$3M	Buy	96,350 +67,010	+228%	+$2.07M	0.01%	795
2021 Q2	$786K	Sell	29,340 -99,900	-77%	-$2.93M	﹤0.01%	1161
2021 Q1	$4.01M	Buy	+129,240	New	+$4.89M	0.01%	622

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings's NRIX Position: Q1 2025 in Review

Nomura Holdings sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 10,514 shares — an estimated $198K sold.

Nomura Holdings first reported a position in NRIX in Q1 2021 and held it in 11 quarters. The position peaked at $5.15M in Q4 2021. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

Nomura Holdings reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
Nomura Holdings sold 10,514 Nurix Therapeutics shares in Q1 2025, an estimated $198K.
Nomura Holdings first reported a position in Nurix Therapeutics in Q1 2021 and held it in 11 quarters.
Nomura Holdings's Nurix Therapeutics position peaked at $5.15M in Q4 2021.
170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Nomura Holdings's 13F filing for Q1 2025, filed 15 May 2025.